Karen Quadrini
Director, Clinical Biomarkers Prothena Corporation
Seminars
Tuesday 3rd February 2026
Roundtable Discussion: Harmonising Fluid‑Biomarker Assays Across Sites for Regulatory Confidence
3:00 pm
- Aligning plasma p‑Tau217 assays and shared cut‑offs across trial labs standardises early‑stage Alzheimer’s screening and cuts unnecessary PET scans and enrolment delays
- Quantifying the α‑synuclein RT‑QuIC seeding assay with synthetic calibrators converts a yes/no read‑out into a dose‑response biomarker, permitting smaller, mechanism‑rich Parkinson’s studies
- Benchmarking CSF dopa‑decarboxylase alongside NFL in AMP‑PD biobank samples harmonises Parkinson’s progression metrics across sites and boosts regulator confidence in multicentre data packages
Tuesday 3rd February 2026
Panel Discussion: Deciphering the Landscape of Emerging Neurodegenerative Fluid Markers Beyond p-tau & α-Synuclein
9:00 am
- GBA, LRRK2, and TREM2: Where do these emerging targets stand in terms of measurable, scalable biomarkers?
- What should define a ‘clinically useful’ biomarker when translatability remains uncertain?
- How do we ensure fluid biomarkers reflect causal disease biology rather than downstream noise?
Tuesday 3rd February 2026
Chair’s Opening Remarks
8:55 am
